The role of registries in hematological disorders

IF 2.2 4区医学 Q3 HEMATOLOGY

Best Practice & Research Clinical Haematology Pub Date : 2024-06-01 DOI:10.1016/j.beha.2024.101556

Helen Baldomero , Daniel Neumann , Nada Hamad , Yoshiko Atsuta , Anna Sureda , Minako Iida , Amado Karduss , Alaa M. Elhaddad , Nosa G. Bazuaye , Carmem Bonfim , Rafael de la Camara , Naeem A. Chaudhri , Fabio Ciceri , Cinthya Correa , Cristobal Frutos , Sebastian Galeano , Laurent Garderet , Raffaella Greco , Gregorio Jaimovich , Yoshihisa Kodera , Dietger Niederwieser

{"title":"The role of registries in hematological disorders","authors":"Helen Baldomero , Daniel Neumann , Nada Hamad , Yoshiko Atsuta , Anna Sureda , Minako Iida , Amado Karduss , Alaa M. Elhaddad , Nosa G. Bazuaye , Carmem Bonfim , Rafael de la Camara , Naeem A. Chaudhri , Fabio Ciceri , Cinthya Correa , Cristobal Frutos , Sebastian Galeano , Laurent Garderet , Raffaella Greco , Gregorio Jaimovich , Yoshihisa Kodera , Dietger Niederwieser","doi":"10.1016/j.beha.2024.101556","DOIUrl":null,"url":null,"abstract":"<div><p>Hematopoietic cell transplantation (HCT) was developed more than 65 years ago to treat malignant blood disorders and irreversible bone marrow failures, with the aim of replacing a diseased hematopoietic system with a healthy one (allogeneic HCT). Decades later, the procedure was adapted to apply maximal chemotherapy or radiotherapy, which would result in bone marrow failure, but could be remedied by an infusion of a patient's own cryopreserved bone marrow (autologous HCT). Both treatments are high-risk and complex, especially during the initial phases. However, concerted efforts, vision, and collaboration between physicians and centers worldwide have resulted in HCT becoming a standard of care for many hematological disorders with progressive improvements in outcomes. Registries and the collaboration of societies worldwide have enabled the delivery of this curative therapy to many patients with fatal hematological diseases. More than 1.5 million HCT were performed between 1957 and 2019, and activity is continuously increasing worldwide.</p></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"37 2","pages":"Article 101556"},"PeriodicalIF":2.2000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Haematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521692624000227","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hematopoietic cell transplantation (HCT) was developed more than 65 years ago to treat malignant blood disorders and irreversible bone marrow failures, with the aim of replacing a diseased hematopoietic system with a healthy one (allogeneic HCT). Decades later, the procedure was adapted to apply maximal chemotherapy or radiotherapy, which would result in bone marrow failure, but could be remedied by an infusion of a patient's own cryopreserved bone marrow (autologous HCT). Both treatments are high-risk and complex, especially during the initial phases. However, concerted efforts, vision, and collaboration between physicians and centers worldwide have resulted in HCT becoming a standard of care for many hematological disorders with progressive improvements in outcomes. Registries and the collaboration of societies worldwide have enabled the delivery of this curative therapy to many patients with fatal hematological diseases. More than 1.5 million HCT were performed between 1957 and 2019, and activity is continuously increasing worldwide.

查看原文本刊更多论文

登记册在血液病中的作用

造血细胞移植（HCT）是 65 年前为治疗恶性血液疾病和不可逆转的骨髓衰竭而开发的，目的是用健康的造血系统取代病变的造血系统（异基因 HCT）。几十年后，这种治疗方法被调整为应用最大限度的化疗或放疗，这将导致骨髓衰竭，但可以通过输注患者自身冷冻保存的骨髓来补救（自体造血干细胞移植）。这两种治疗方法都具有高风险和复杂性，尤其是在初始阶段。然而，经过全球医生和中心的共同努力、远见卓识和通力协作，自体造血干细胞移植已成为许多血液病的标准治疗方法，治疗效果也在逐步改善。登记册和全球各协会的合作，使这种治疗方法能够惠及许多致命血液病患者。1957年至2019年期间，共进行了150多万例造血干细胞移植，而且全球范围内的活动还在持续增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Best Practice & Research Clinical Haematology 医学-血液学

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

35 days

期刊介绍： Best Practice & Research Clinical Haematology publishes review articles integrating the results from the latest original research articles into practical, evidence-based review articles. These articles seek to address the key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach which focuses on the key questions to be addressed, clearly defining what is known and not known, covering the spectrum of clinical and laboratory haematological practice and research. Although most reviews are invited, the Editor welcomes suggestions from potential authors.